^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    BCL2A1 (BCL2 Related Protein A1)

    i
    Other names: BCL2A1, BCL2 Related Protein A1, Hemopoietic-Specific Early Response Protein, Bcl-2-Related Protein A1, Bcl-2-Like Protein 5, Protein BFL-1, Bcl2-L-5, BCL2L5, HBPA1, BFL1, GRS, Hematopoietic BCL2-Related Protein A1, Protein GRS, ACC-1, ACC-2, ACC1, ACC2
    4d
    Canady Helios Cold Plasma Induces Non-Thermal (24 °C), Non-Contact Irreversible Electroporation and Selective Tumor Cell Death at Surgical Margins. (PubMed, Cancers (Basel))
    This study demonstrates CHCP as a non-thermal (24 °C), non-contact plasma-based IRE platform which induces controlled membrane permeabilization and selective cancer cell death. CHCP offers a translational strategy to eradicate residual tumor cells at the surgical margins, and prevent local recurrence, positioning it as a versatile adjunct in precision surgical oncology.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor) • BCL2A1 (BCL2 Related Protein A1)
    |
    HER-2 negative
    12d
    Linking the Warburg effect to endometrial receptivity: metabolic parallels in embryo implantation. (PubMed, Front Cell Dev Biol)
    Targeting this shared metabolic-immune-hormonal axis holds immense potential for developing innovative strategies (e.g., metabolic modulators, refined TCM approaches) to improve ER, enhance embryo implantation rates in infertility (including IVF) and recurrent miscarriage, ultimately advancing global reproductive health. Further research is needed to validate core mechanisms.
    Review • Journal
    |
    BCL2A1 (BCL2 Related Protein A1) • TGFB1 (Transforming Growth Factor Beta 1) • PFKFB3 (6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase 3) • SLC2A1 (Solute Carrier Family 2 Member 1)
    18d
    Gene Expression Profiling Provides an Improved Characterization of CD79B-Mutated Diffuse Large B-Cell Lymphomas. (PubMed, J Pers Med)
    TP53 mutation showed an association with poorer overall survival in a secondary analysis, consistent with prior reports, while survival by CD79B/MYD88 mutation status and the differentially expressed genes showed no significant differences in this cohort. In conclusion, the current study identified novel up-regulated genes in CD79B-mutated DLBCLs beyond NF-κB pathway signaling, which may contribute to a better definition of potential therapeutic targets and further improves the characterization of this distinct and aggressive DLBCL subgroup.
    Journal
    |
    TP53 (Tumor protein P53) • MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • RUNX1 (RUNX Family Transcription Factor 1) • CD79B (CD79b Molecule) • RUNX1T1 (RUNX1 Partner Transcriptional Co-Repressor 1) • STAT3 (Signal Transducer And Activator Of Transcription 3) • CARD11 (Caspase Recruitment Domain Family Member 11) • IL10 (Interleukin 10) • CD14 (CD14 Molecule) • PIM1 (Pim-1 Proto-Oncogene) • BCL2A1 (BCL2 Related Protein A1) • GZMB (Granzyme B) • IL7 (Interleukin 7) • RASGRF1 (Ras Protein Specific Guanine Nucleotide Releasing Factor 1) • AFDN (Afadin, Adherens Junction Formation Factor) • HSP90AB1 (Heat Shock Protein 90 Alpha Family Class B Member 1) • WNT11 (Wnt Family Member 11)
    |
    TP53 mutation
    26d
    Development of a single-cell derived MDSCs signature score for prognostic risk stratification and therapeutic decision guidance in breast cancer. (PubMed, Transl Oncol)
    This investigation marks the initial systematic characterization of a new MDSCs gene signature in breast cancer, alongside the establishment of an MDSCs-associated marker scoring framework with multi-aspect clinical translation capability, thereby linking MDSCs fundamental biology to precision oncology in this cancer type.
    Journal • IO biomarker
    |
    BCL2A1 (BCL2 Related Protein A1) • RNASE1 (Ribonuclease A Family Member 1) • SERPINA1 (Serpin Family A Member 1)
    1m
    Integrating computational pathology and multi-transcriptomics to characterize glioblastoma heterogeneity and identify prognostic biomarkers. (PubMed, Hum Pathol)
    Integration of computational pathology and multi-transcriptomic data identified BCL2A1+ monocytes as drivers of angiogenesis and progression. This approach offers a prognostic tool and potential therapeutic targets for GBM.
    Journal
    |
    BCL2A1 (BCL2 Related Protein A1)
    1m
    Intratumoral SPP1+BCL2A1+ Tumor-Associated Macrophages Predict Poor Response to PD1 Blockade. (PubMed, Diagnostics (Basel))
    Our findings identify SPP1+BCL2A1+ TAMs as a poor prognostic biomarker in HCC patients undergoing ICB therapy. By promoting an immunosuppressive microenvironment, SPP1+BCL2A1+ TAMs, which are survival-advantaged, may represent both a predictive marker and a potential therapeutic target to enhance the efficacy of immunotherapy.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • PD-1 (Programmed cell death 1) • SPP1 (Secreted Phosphoprotein 1) • BCL2A1 (BCL2 Related Protein A1)
    1m
    Exploring the prognostic value of T cell exhaustion and mitochondrial dysfunction related genes in breast cancer through bioinformatics analysis and RT-qPCR validation. (PubMed, Clin Exp Med)
    The accurate risk model stratified patients: high-risk correlated with suppressed immunity (p < 2.2e-16), elevated TIDE (p = 5.4e-14), and higher CI.1040 IC50 (cor = 0.63, p < 0.0001)...Risk score, age, race, N/M-stage were independent factors. Seven prognostic genes effectively predicted BRCA prognosis with independent prognostic factors.
    Journal • BRCA Biomarker
    |
    CD74 (CD74 Molecule) • BRCA (Breast cancer early onset) • BCL2A1 (BCL2 Related Protein A1) • GZMB (Granzyme B) • PPP1R15A (Protein Phosphatase 1 Regulatory Subunit 15A) • IRF7 (Interferon Regulatory Factor 7) • MTHFD2 (Methylenetetrahydrofolate Dehydrogenase (NADP+ Dependent) 2)
    |
    CI-1040
    3ms
    Identification and Validation of Mitochondria-Related Genes for Diagnosis of Early-Stage Sepsis. (PubMed, Ann Clin Lab Sci)
    These findings suggest that mitochondrial dysfunction plays a critical role in sepsis progression, and the identified genes may serve as biomarkers for early diagnosis and targeted treatment, potentially improving patient outcomes.
    Journal
    |
    BCL2 (B-cell CLL/lymphoma 2) • BCL2A1 (BCL2 Related Protein A1) • ARG2 (Arginase 2) • IFI27 (Interferon Alpha Inducible Protein 27)
    3ms
    Sensitivity of Pediatric Myelodysplastic Syndromes With Excess of Blasts With UBTF-TD to Venetoclax/Azacitidine. (PubMed, Am J Hematol)
    All patients are disease-free and graft-versus-host disease-free at last follow-up. Comprehensive biological characterization of the disease showed (i) high expression of the BCL2 gene, paralleled by a low expression of BCL2A1 and MCL1; (ii) overexpression of both HOXA and HOXB; and (iii) a distinct methylation signature of patients with UBTF-TD myeloid neoplasms.
    Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • MCL1 (Myeloid cell leukemia 1) • BCL2A1 (BCL2 Related Protein A1)
    |
    Venclexta (venetoclax) • azacitidine
    3ms
    Upregulation of EMP3 in acute myeloid leukemia: a study based on data mining, RT-qPCR and immunohistochemistry. (PubMed, Discov Oncol)
    These findings suggest that EMP3 overexpression occurs in AML and potentially influences disease prognosis.
    Journal
    |
    BCL2A1 (BCL2 Related Protein A1) • ITGAM (Integrin, alpha M)
    5ms
    The potential role of BCL2A1⁺ tissue-resident macrophages in the prognosis of Wilms tumor. (PubMed, Eur J Med Res)
    Functional enrichment analysis suggests that BCL2A1⁺tissue-resident macrophages may promote WT progression through immune regulation and apoptosis pathways. This study is the first to identify the presence of a BCL2A1⁺tissue-resident macrophage subset in WT and reveal its critical role in tumor progression, potentially providing a novel target for personalized immunotherapy.
    Journal • IO biomarker
    |
    BCL2A1 (BCL2 Related Protein A1)
    5ms
    COP1 Deficiency in BRAFV600E Melanomas Confers Resistance to Inhibitors of the MAPK Pathway. (PubMed, Cells)
    Indeed, the deletion of pro-survival BCL2A1 re-sensitized COP1 mutant cells to vemurafenib treatment. These observations indicate that the post-translational regulation of ETV5 by CRL4COP1/DET1 modulates transcriptional outputs in ERK-dependent cancers, and its inactivation contributes to therapeutic resistance.
    Journal
    |
    ETV1 (ETS Variant Transcription Factor 1) • BCL2A1 (BCL2 Related Protein A1) • ETV5 (ETS Variant Transcription Factor 5) • ETV4 (ETS Variant Transcription Factor 4)
    |
    BRAF V600E • BRAF V600
    |
    Zelboraf (vemurafenib)